Hong Kong Transportation Stock News

SEHK:883
SEHK:883Oil and Gas

Assessing CNOOC (SEHK:883) Valuation After Recent Share Price Momentum

Why CNOOC Shares Are Back on Investors' Radar CNOOC (SEHK:883) has caught investor attention again, with the share price moving 2.5% over the past day and showing double digit returns over the past month and past 3 months. See our latest analysis for CNOOC. That 2.5% 1 day share price gain sits within a strong upswing, with a 30 day share price return of 14.23%, a 90 day share price return of 41.84%, and a 1 year total shareholder return of 68.17%. This points to building momentum rather than...
SEHK:9926
SEHK:9926Biotechs

Asian Growth Companies Insiders Are Eager To Own

In the face of global market volatility and geopolitical tensions, Asian markets have shown resilience amid rising energy prices and economic uncertainties. With central banks signaling caution due to inflation risks, investors are increasingly turning their attention to growth companies with high insider ownership, which can often indicate strong confidence in a company's potential amidst challenging conditions.
SEHK:9926
SEHK:9926Biotechs

3 Asian Stocks Estimated To Be Up To 44.5% Below Intrinsic Value

In the current landscape, Asian markets are navigating through heightened geopolitical tensions and fluctuating energy prices, contributing to a complex economic environment. Amidst these challenges, identifying undervalued stocks can offer potential opportunities for investors seeking value in a turbulent market. Recognizing stocks trading below their intrinsic value may provide an edge in capitalizing on long-term growth prospects despite short-term uncertainties.
SEHK:1515
SEHK:1515Healthcare

China Resources Medical Holdings SEHK 1515 Margin Dip Tests Bullish Long Term Growth Narratives

China Resources Medical Holdings (SEHK:1515) has reported its FY 2025 first half numbers with revenue of C¥4.5b and basic EPS of C¥0.27, alongside net income of C¥339.5m, setting a clear reference point against prior periods. Over recent halves, the company has seen revenue move from C¥4.98b in 1H 2024 to C¥4.88b in 2H 2024 and C¥4.52b in 1H 2025, with basic EPS shifting from C¥0.34 in 1H 2024 to C¥0.10 in 2H 2024 and C¥0.27 in 1H 2025. For investors, the key question now is how these...
SEHK:154
SEHK:154Commercial Services

Beijing Enterprises Environment Group SEHK 154 Margin Compression Challenges Bullish Earnings Narratives

Beijing Enterprises Environment Group (SEHK:154) just posted its FY 2025 first half numbers, reporting revenue of C¥722.4 million and basic EPS of C¥0.085, with net income excluding extra items at C¥127.1 million. Trailing 12 month revenue was C¥1.4 billion and basic EPS was C¥0.155. The company reported revenue of C¥803.2 million and basic EPS of C¥0.094 in 1H FY 2024, followed by revenue of C¥860.9 million and EPS of C¥0.100 in 2H FY 2024. Trailing 12 month net income excluding extra items...
SEHK:3858
SEHK:3858Metals and Mining

Jiaxin International Resources Investment (SEHK:3858) Returns To HK$305.1m TTM Profit Challenging Bearish Narratives

Jiaxin International Resources Investment (SEHK:3858) has put out its FY 2025 numbers with first half revenue of HK$126.3 million and a basic EPS loss of HK$0.018, against a trailing twelve month picture that includes HK$1.1 billion in revenue and EPS of HK$0.82. Over recent periods the company has moved from zero revenue in both halves of FY 2024, when EPS losses were HK$0.193 and HK$0.332, to the current revenue base and a positive trailing EPS figure, giving you a very different backdrop...
SEHK:586
SEHK:586Construction

China Conch Venture Holdings (SEHK:586) Margin Lift Reinforces Bullish Narratives Despite Flat Revenue

China Conch Venture Holdings (SEHK:586) has put up a clean set of numbers for FY 2025 so far, with first half revenue of C¥3.1b and basic EPS of C¥0.76, alongside trailing twelve month revenue of C¥6.5b and EPS of C¥1.32. The company has seen revenue hold around the C¥3.1b mark across recent half year periods, while basic EPS has moved between C¥0.49 and C¥0.76 per half. This has fed into trailing twelve month net income of C¥2.2b and a higher net margin over the last year, which frames this...
SEHK:2595
SEHK:2595Biotechs

GenFleet Therapeutics SEHK 2595 Deepens Losses As Revenue Growth Tests Bullish Narratives

GenFleet Therapeutics (Shanghai) (SEHK:2595) has just released its FY 2025 figures, with first half revenue at C¥88.7 million and basic EPS at a loss of C¥27.02 per share, setting the tone for a period where margins remain firmly in loss-making territory. The company has seen first half revenue move from C¥0 in 2024 to C¥88.7 million in 2025, while basic EPS shifted from a loss of C¥18.02 to a deeper loss of C¥27.02. This puts the spotlight on how quickly revenue can scale against persistent...